Upcoming Pharm-Olam Webinar Helps Sponsors Manage Rescue Study Transitions
Houston, June 10th, 2019 – Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology-hematology, infectious diseases and vaccines and rare diseases, will be sharing key strategies for pharmaceutical companies needing to transition studies to a different CRO in a free webinar on June 18.
The webinar, “Rescuing Your Study – A Sponsor’s Playbook,” will present insights from more than 100 rescue studies that Pharm-Olam has saved. Presenters are Shannon Hambridge, vice president of global project management, and Sarah Liddiard, senior director of global project management.
“Migrating a study to a new CRO can be time-consuming and fraught with unexpected difficulties,” said Liddiard. “We will share some best practices to help sponsors successfully navigate pain points or avoid them altogether.”
During the webinar, speakers will cover the following topics:
- Tips and advice for planning your study transition
- What to provide to CROs bidding to save your trial
- How long to allow for full transition
- How to keep outgoing and incoming CROs informed
- How to manage and support outgoing and incoming CROs
- Common pain points
- Tips and considerations for contractual requirements
“When a sponsor is faced with a study that needs rescuing, it is often because of quality, recruitment, study management or financial management problems,” said Hambridge. “Too often, these transfers are marked by confusion and stress. By leveraging the expertise we’ve gained by rescuing numerous studies, we will give sponsors valuable information to proactively manage and streamline the transition of current and future rescue studies.”
Registration for the webinar is available here.
Pharm-Olam is Helping Create a Healthier World as a global, midsized CRO that offers flexible, innovative, and highly personalized clinical solutions to pharmaceutical, biotechnology, and life science companies. Our team is well-known for producing quality results with reduced risk, costs, and timelines in challenging international trials. Learn more about our full-service solutions, data protection services, and expertise in oncology, infectious diseases and vaccines, rare and orphan diseases, pediatrics, and general medicine at pharm-olam.com.